Total votes: 2

ResMed (NYSE: RMD and ASX: RMD) is a leading developer, manufacturer and marketer of products for the screening, treatment and long-term management of sleep-disordered breathing (SDB) and other respiratory disorders. ResMed operates in over 68 countries via 18 direct offices and a network of distributors with extensive knowledge and experience of local markets.

ResMed's device for treating obstructive sleep apnea (OSA), a major subset of SDBaddresses nasal continuous positive airway pressure (CPAP) and provided the first successful noninvasive treatment of OSA. SDB affects around 20% of the adult population, making it as widespread as diabetes or asthma. However, awareness is low and we believe that about 90% of people who have OSA remain undiagnosed and untreated.

The term “sleep-disordered breathing” includes a spectrum of respiratory disorders ranging in severity from snoring to OSA. OSA occurs when the airway temporarily collapses during sleep, preventing or restricting breathing for up to ten seconds or more. Such events can occur several hundred times a night severely disrupting sleep.

Financial snapshot:

Resmed said its net profit for the three months to September 30 was $US50.5 million ($A48.35 million), down from $US56.7 million ($A54.28 million) in the previous corresponding period.

The company continues to invest approximately 6% of revenues in research and product development.